Gauthier Delomez / Photo credits: Benoit Durand / Hans Lucas / Hans Lucas via AFP
The prestigious journal “The Lancet Neurology” published this Tuesday a study carried out by French researchers, from the company Acticor Biotech, which shows the effectiveness of a new treatment in cases of stroke. Taking Glenzocimab, a drug that thins the blood, in addition to Thrombolysis, could reduce the risk of mortality by half.
It is a treatment developed by a French company, Acticor Biotech, which raises hope among patients who have suffered a stroke. Researchers published a study this Tuesday in the prestigious journal The Lancet Neurologyshowing that taking Glenzocimab, a drug that thins the blood, in addition to Thrombolysis (a treatment already used for stroke, editor’s note) could reduce the risk of mortality.
140,000 people suffer from a stroke each year
Questioned by France Inter which revealed this study, Professor Mikaël Mazighi, head of the neurology department at Lariboisière hospital in Paris and one of the co-authors, explains that “this medication will prevent the formation of clots (post-stroke , editor’s note), but it will not increase the risk of bleeding.” The key, therefore, is a reduction in mortality. In this study, “patients not receiving the drug had a mortality of 19% and patients receiving the drug had a mortality reduced to 8%, therefore more than 50% reduction in mortality,” reports Mikaël Mazighi.
The study was carried out on more than 160 patients who had suffered an acute ischemic stroke (80% of cases in France), in six European countries. Its results are encouraging, while with current treatments, 54% of patients have significant after-effects, according to Le Figaro.
In France, 140,000 people suffer from stroke each year, according to the Ministry of Health. In total, 40,000 patients die from it, making it the third cause of death in the country and the first among women. Stroke is also the leading cause of acquired disability.